https://www.selleckchem.com/pr....oducts/sb290157-tfa.
9%, P = .013) and presence of EGFR (+) mutations (66.7% vs 33.3%, P = .04). Survival analysis carried out in the whole population did not show any association of CD47 expression and survival outcome. However, in patients with EGFR (+) mutations, CD47 expression was associated with higher progression-free survival (PFS) (12.2 vs. 4.4 months, P = .032). When the survival analysis was performed according to CD47 levels (cut off value 15, both, PFS and overall survival (OS) were shortened in patients with a high expression of CD47 (1
Like
Comment
Share
